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Abstract 
Background: Chronic Hepatitis C virus (HCV) is an infection associated with an increased risk of cirrhosis, hepatocellular carcinoma 
(HCC), and morbidity and mortality. Treating HCV poses challenges in the elderly population due to the lack of evidence and complexity 
of patients. 
Objective: This study aims to evaluate factors that influence HCV treatment success in elderly patients, especially those over age of 70, 
such as pill burden and comorbidities, in addition to drug interactions and adverse effects. 
Methods: This was a retrospective chart review of patients treated at our urban academic institution from 2014-2016. 
Results: Sixty-two patients over the age of 70 were included in this study. The sustained virologic response rate 12 weeks after the 
completion of treatment (SVR12) was 79%. In a multi-variate analysis, cirrhosis, age closer to 70, and longer duration of treatment 
were statistically significantly more likely to lead to treatment failure. Though not statistically significant, other factors that may 
negatively influence achievement of SVR12 were cognitive impairment, cardiovascular disease, multi-tablet HCV regimen, time to 
initiation of HCV treatment > 90 days, and prior treatment experience. Pill burden of other prescribed medications did not impact 
SVR12. Adverse events and drug interactions were common in the population. 
Conclusions: Overall SVR12 rate in the elderly population was lower than that reported in the literature. Factors associated with lower 
treatment success, especially cirrhosis, should be considered when treating an elderly population. Further data is needed on the impact 
of other factors on SVR12 attainment in an elderly patient population. 
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Introduction 
Chronic Hepatitis C virus (HCV) is an infection associated with 
an increased risk of cirrhosis, hepatocellular carcinoma (HCC), 
and morbidity and mortality.1 HCV can also cause extrahepatic 
manifestations such as diabetes, renal impairment, cognitive 
impairment, and cardiovascular disease, among others.2 It is 
estimated that almost 4 million people are affected by HCV in 
the United States (US). Although HCV can affect all age groups, 
one of the most impacted groups is estimated to be in those 
born between the years of 1945-1965.3,4 Patients in this age 
cohort are beginning to turn 70 years of age and soon all 
members of this cohort will exceed 70 years of age. 
  
It is imperative to understand how age affects cirrhosis due to 
the aging population of patients with HCV. Cirrhosis is an 
advanced degree of fibrosis with hepatic vasculature 
alterations that lead to portal hypertension and end-stage liver 
disease.5.6 Studies have demonstrated that increased duration 
of HCV infection are risk factors for progression to worsening 
fibrosis stages and cirrhosis.7,8 Cirrhosis most commonly affects 
patients 60 to 80 years of age.9 A retrospective cohort of 
Veterans Affairs (VA) patients demonstrated that the age of 
patients with cirrhosis has increased from a mean 57.3 years  
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(SD 10.5) in 2001 to 62.4 (SD 8.4) in 2013 and HCV was seen in 
an increased proportion of patients.10 Achieving clinical cure or 
sustained virologic response (SVR) 12 weeks (SVR12) after 
treatment completion decreases the risk of cirrhosis 
development. In cirrhotic patients, achieving SVR12 can 
decrease the likelihood of decompensation and lower the risk 
of HCC.3 
  
Prior to 2011, HCV treatment was interferon (IFN) -based, 
leading to increased adverse effects (AEs) and poor patient 
outcomes, especially in an elderly population.11 Many elderly 
patients were not treated due to comorbidities affecting 
eligibility and AE profiles. Since then, highly effective oral direct 
acting antivirals (DAAs) have been approved by the Food and 
Drug Administration and have significantly improved patient 
outcomes with SVR12 rates exceeding 90%, however few 
elderly patients were included in these studies.1,3,12,13 The high 
efficacy and decreased pill burden of DAAs was accompanied 
by high costs of therapy and delays in access. A retrospective 
cohort study including 9025 patients from 45 states found that 
35.5% were denied treatment, with the largest number coming 
from commercial insurance companies.14 Often, patients were 
prioritized for treatment from insurance companies based on 
presence of more severe hepatic dysfunction and HIV co-
infection. When elderly patients have been evaluated in real-
world studies, SVR12 rates were comparable to the general 
population.15-17 Despite similar SVR12 rates, elderly patients 
remain difficult to treat due to increasing presence of comorbid 
disease states, which may be worsened by HCV infection, and 
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higher pill burden. Both factors may increase the likelihood of 
drug interactions (DIs) and AEs. 
  
Over 87% of the US population between the ages of 62 and 85 
takes at least one medication daily according to a 2011 survey 
and 35% take more than 5 medications daily.18 Adherence to 
medication is a contributor to achieving optimal outcomes. Pill 
burden, or number of pills a patient must take per day, may 
impact adherence and thus, HCV treatment success. Higher pill 
burden has demonstrated negative effects on adherence and 
outcomes in diseases such as hypertension and human 
immunodeficiency virus (HIV) and should be considered when 
selecting therapy in the elderly population.19-22 Data from the 
Accurate Dosing in Hepatitis C: Examining the RibaPak 
Experience (ADHERE) registry assessed how traditional RBV and 
RibaPak (RBP) affected HCV treatment adherence, since RBP is 
a twice daily regimen with lower pill burden.23 Patients using 
RBP were more adherent to therapy, defined as taking  ≥80% of 
doses, at both 12 weeks and 24 weeks compared to those using 
RBV (p = 0.02 and p<0.05, respectively), but no clinical 
outcomes were assessed.23 No studies on the effect of pill 
burden on adherence and clinical outcomes has been published 
in the DAA era. 
  
The prevalence of DIs in patients taking DAAs is relatively high, 
due to their effects on multiple transporter systems and altered 
drug metabolism. Elderly patients may be at a greater risk for 
DIs and AEs, due to a larger number of concomitant 
medications for multiple comorbidities.25,26 A small 
retrospective study from Germany described the DIs and 
adverse effects faced by elderly patients receiving DAAs.24 The 
proportion of predicted clinically significant DIs was 
significantly higher in patients greater than 65 years of age, 
(54% vs. 28%; P < 0.0001) indicating that medication use should 
be evaluated, but SVR12 was high in patients over age 65.24 A 
study with 221 patients on DAAs with or without RBV showed 
that participants of older age, defined as greater than 75 years, 
were more likely to experience a more serious (grade 3-4) AE.16  
  
Our institution is a large academic medical center in an urban 
environment serving a large number of patients with multiple 
comorbidities. Upon the decision to treat HCV by a provider, a 
clinical pharmacist meets with the patient to initiate and 
manage DAA treatment. Once a DAA is started, the patient is 
followed by a clinical pharmacist, a nurse, and a provider. This 
study aims to evaluate other factors, such as pill burden and 
comorbidities, that impact HCV treatment outcomes in elderly 
patients, including DDIs and AEs.  
 
Methods 
This was a single-center retrospective evaluation of HCV mono-
infected patients who were at least 70 years old, or “elderly” 
patients, at the time of HCV therapy initiation at our institution. 
EPIC (Epic Systems Corporation, Verona, Wisconsin) medical 
records were evaluated for all patients that began DAA therapy 
between June 2014 and September 2016 in the Hepatology and 
Gastroenterology departments at our institution. Treatment 
regimens and duration were determined based on standard of 
care guidelines and insurance coverage at the time of 
treatment.3 
  
The primary outcome was the achievement of SVR12, defined 
by an undetectable HCV ribonucleic acid (RNA) twelve weeks 
after completion of DAAs. Secondary outcomes included SVR12 
by regimen, comorbidity, treatment experience, pill burden, 
and time to treatment initiation. The number and type of DIs 
and reported AEs were also evaluated. Comorbidites of 
interest, defined by the problem list or laboratory findings in 
EPIC, included cirrhosis (Fibrosis stage of F4 and progress note 
documentation), cognitive impairment (dementia or cognitive 
impairment), renal dysfunction (Estimated Glomerular 
Filtration Rate (EGFR) <60 mL/min), diabetes (HgbA1C >6.5%), 
and cardiovascular disease. Medication and pill burden was 
determined by the counting the number of oral medications 
and the tablets and/or capsules (referred to as pills) that a 
patient was taking on the start date of DAAs as documented in 
EPIC. Medications taken as needed were assessed by 
medication count and pill burden. A medication dosed weekly 
was counted as one pill. Time to treatment initiation was 
calculated as the time between the initial decision to treat per 
progress notes and the date the patient began DAAs. Clinic visit 
notes were reviewed to determine if AEs occurred and if DIs 
existed. 
  
All patients over age 70 treated for HCV within the defined 
period were included. No patients were excluded. Categorical 
variables were expressed as percentages, and continuous 
variables were expressed as medians with interquartile ranges. 
Pearson chi-square test was performed for categorical variables 
and a two-sample t-test for continuous variables. A 
multivariable logistic regression model evaluated variables that 
predicted SVR based on a p-value <0.1 with univariate analysis. 
Spearman test was used to determine correlation between 
variables prior to performing multivariable logistic regression. 
AORs with 95% CIs are reported for the final logistic regression 
models. All statistical analyses were performed using Stata 
release 14 (StataCorp, College Station, Texas). An a priori 
significance level of 0.05 was used. 
  
Results 
Sixty-two patients were included in the study and received     
HCV treatment. Table 1 provides pertinent demographic 
information. Among the participants, the mean [SD] age was 73 
[2.88] years and most patients were female and African 
American. Over 90% of patients had genotype 1a or 1b and 
were treatment naive. Cirrhosis was evident in 58% of patients. 
Other comorbidities present included diabetes, cardiovascular 
disease, cognitive impairment, and renal impairment evidenced 
by an estimated eGFR <60 ml/min. 
  
Original Research PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                        2019, Vol. 10, No. 3, Article 14                        INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v10i3.2144 
3 
 
The primary outcome of SVR12 achievement was assessed in 61 
patients (1 patient lost to follow-up). Of 61 patients, 49 (79%) 
achieved SVR12 overall. The average age of patients who 
achieved SVR12 was older than the treatment failures (74.04 vs 
70.67, p=0.003). Table 2 summarizes factors evaluated as 
influencers of SVR12 attainment based on the univariate 
analysis. SVR12 was achieved in statistically significantly more 
non-cirrhotic patients than with cirrhosis (p=0.001). The 
presence of diabetes, cardiovascular disease, and cognitive 
impairment was associated with a lower rate of SVR12, 
however only the presence of cognitive impairment (p=0.049) 
was statistically significantly associated with treatment failure. 
Twenty-two patients had more than one comorbid condition. 
Presence of multiple comorbidities reduced SVR12 rate; 
treatment failures had an average of 2.16 conditions, while 
successful treatment had an average of 1.32 condition (p=0.02). 
As number of comorbidities increased, SVR12 was 73% in those 
with 2 or more comorbidities, but decreased to 50% in the 4 
patients with 4 or more comorbidities achieved SVR12. 
  
Individual SVR12 rates varied among agents: LDV/SOF +/- RBV 
82%, SMV/SOF 40%, and 100% for SOF/RBV, EBR/GZR, and 
other regimens (PrOD + RBV) and SOF + daclatasvir + RBV. Of 
the 12 patients without SVR12 achievement, five received 
LDV/SOF for 12 weeks, three LDV/SOF for 24 weeks, one 
LDV/SOF + RBV for 24 weeks, one SIM/SOF for 12 weeks, and 
two SMF/SOV for 24 weeks. Patients with genotype 1 had an 
SVR12 of 78.5%, while patients with mixed genotypes or 
genotype 2 had an SVR12 of 100%. There was no statistical 
difference in SVR12 achievement by genotype. Overall, SVR12 
rates were greatest in those treated for shorter durations 
compared to 24 weeks (8 weeks 100%; 12 weeks 83.78%; 16 
weeks 100%; 24 weeks 50%). Duration of treatment 
significantly impacted SVR12. The 12 treatment failures were 
treated for a mean of 18 weeks compared to the 49 successfully 
treated patients taking DAAs for a mean of 12.8 weeks 
(p=0.002). SVR12 was achieved in more patients on a single-
tablet daily HCV regimen than on a multi-tablet HCV regimen. 
The 22 treatment experienced patients achieved SVR12 at a 
lower rate than treatment naive patients. 
  
The average number of concomitant medications that patients 
were taking daily was approximately 8, ranging from 1 to 29 
medications/day. Due to several medications requiring multiple 
administrations daily, the average daily pill burden was 
approximately 9 tablets/day with a range of 1 to 33 tablets/day. 
Several patients also reported taking PRN medications, with an 
average of 2 tablets/day and a range of 0-14 tablets/day.  Of 
patients taking 9 or more medications daily, 82% achieved 
SVR12 (n=27). In contrast, those taking less than 9 tablets daily 
reported similar results with approximately 79% (n=22) 
attaining SVR12. 
  
The average time to treatment initiation was approximately 97 
days. A delay in treatment initiation was reported in 80% (n=50) 
of patients, with the most commonly reported reason for delay 
being insurance authorization in 46% (n=29) of cases. Other 
reasons noted for delayed treatment included pending lab 
results (n=10), communication difficulties with patients (n=7), 
and other health concerns (n=8) including altered mental 
status, emergency room visits, or awaiting other procedures. 
Several patients had multiple reasons for treatment delay (i.e. 
pending insurance approval, requiring lab results) and 19% 
(n=12) did not have reasons listed regarding treatment delays. 
In the 23 patients waiting more than 90 days to begin 
treatment, SVR12 was lower than in the 38 patients waiting less 
than 90 days to begin treatment. 
  
The multivariate analysis evaluated age at treatment start, 
treatment experience, number of comorbidities, duration of 
treatment, and presence of cognitive impairment. Due to the 
relation between number of comorbidities and treatment 
duration, two multivariate models were conducted. Older age 
at treatment start (AOR 1.88; 95% CI 1.075-3.303; p=0.027) and 
shorter duration of HCV treatment (AOR 0.87; 95% CI 0.763-
0.989; p=0.034) were found to significantly predict treatment 
success in one multivariate model. In the second model, older 
age persisted as a treatment success predictor (AOR 2.11; 95% 
CI 1.16-3.85; p=0.014) as did a lower number of comorbidities 
(AOR 0.52; 95% CI 0.262-1.042; p = 0.66). 
  
Potential DIs were reported in 45% (n=28) of patients, resulting 
in discontinuation or dose adjustment of non-HCV medications 
prior to DAA initiation. Overall, 15 medications were 
discontinued and 13 medications required adjustments in dose 
or time of administration. The most common medications 
implicated in DIs included acid-reducing agents with at least 8 
patients requiring discontinuation or alteration in 
administration time. Other medications that were commonly 
implicated include amlodipine (n=3) and statins (lovastatin, 
rosuvastatin, simvastatin) (n=3). Of note, several patients 
experienced fluctuations in drug levels requiring dose 
adjustments, including both tacrolimus (n=1) and warfarin 
(n=1). Several patients had other medication changes during 
DAA treatment, though unrelated to DIs. During treatment, 32 
participants (52%) experienced one or more AEs. Fatigue (24%), 
headache (8%), appetite changes (8%), and GI abnormalities 
(8%) were most commonly reported. Less common AEs 
included myalgias (5%), hypokalemia (1.5%), and edema (1.5%). 
In patients taking RBV, anemia was not reported, however 
nonspecific AEs such as fatigue were reported. Several patients 
reported incidence of multiple AEs listed, however no 
participants discontinued treatment due to AEs.  
  
Discussion 
The average age of this patient population was 73 years old, 
correlating with the baby boomer population recommended for 
HCV screening. Interestingly, younger patients in our cohort 
achieved SVR12 less than older patients in our cohort, though 
the mean age difference was small (3.3 years). As can be 
Original Research PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                        2019, Vol. 10, No. 3, Article 14                        INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v10i3.2144 
4 
 
expected with an older patient population, many presented 
with comorbidities. When patients presented with multiple 
comorbidities, their chance of achieving SVR12 decreased. 
Cirrhosis was found in 53% of patients, likely as a result of a long 
duration of chronic HCV infection. Presence of cirrhosis was 
found to be the comorbidity that impacted SVR12 rate most. 
DAAs were shown to have lower treatment success in a real 
world study of 15,884 VA patients with cirrhosis [86.8% (95% CI 
85.8–87.7)] or decompensated cirrhosis [82.6% (95% CI 80.5–
84.6)] compared to those without cirrhosis [92.3% (95% CI 
91.8–92.8)], regardless of age.27 Other comorbidities found to 
have a negative effect on SVR12 in our study included diabetes, 
cardiovascular disease, and cognitive impairment. While 
cirrhosis has been documented to have an impact on treatment 
response, this is the first data evaluating the impact of multiple 
comorbidities, including diabetes, cardiovascular disease, and 
cognitive impairment on treatment outcomes. Due to the small 
number of patients in this evaluation, larger studies should 
evaluate the impact of the comorbidities on SVR12. 
  
SVR12 was attained more frequently in patients receiving single 
tablet HCV regimens compared to multiple tablet regimens. 
This may be attributed to a lower pill burden, leading to an 
increased chance of adherence. Patients on multiple tablet 
DAAs may have been more likely to have cirrhosis, but the 
addition of RBV should have helped improve SVR12 rates in this 
population. Patients with cirrhosis were also more likely to be 
on a treatment duration longer than 12 weeks. SIM/SOF had 
the lowest SVR12 rate. Four of the patients had cirrhosis and 
three were treatment experienced; both can lead to lower 
SVR12 achievement.3  Although predicted that overall pill 
burden would have an effect on clinical cure, SVR12 rates in 
patients taking >9 pills/day were similar to those taking <9 
pills/day. Adherence to medications was not systematically 
measured, thus it is difficult to determine the impact of pill 
burden. Patients may have been on background medications 
for any period of time before HCV treatment and been 
adherent, so pill burden may not have impacted adherence and 
treatment success in this patient population. Long delays in 
treatment, such as waiting to treat until patients have attained 
a higher fibrosis stage, may lead to decreased incidence of 
SVR12 attainment and a higher mortality risk.28,29 Specific short-
term delays once decision is made to treat have not yet been 
evaluated. Patients experiencing a treatment delay of >90 days 
resulted in a 17% decrease in SVR12 achievement in this 
evaluation. Thus, it is vital to initiate treatment promptly to 
prevent treatment failure. 
  
DIs were reported in 45% of patients and led to 
pharmacotherapy changes. Many DAAs have known DIs, which 
require dosing adjustments and/or increased monitoring of 
other therapies.30 The high rate of DIs was expected and is 
generally consistent with those discussed in the literature.24 
Over half of the patients experienced AEs, but no patients 
discontinued treatment, which may infer that AEs were minimal 
and tolerated by patients. Patients in this study showed similar 
rates to those previously reported.16 
  
This analysis has several limitations due to the retrospective 
design. Some data points were not available for every patient. 
Only one patient did not receive follow up care at our 
institution and was not included in the results. Follow up rates 
are generally lower in real world analyses; this may indicate 
that elderly patients are more likely to be engaged in care by 
returning for follow up. In comparison to a clinical trial, this 
analysis has a smaller size, lacks a comparator group, and was 
conducted at a single center, making it hard to determine if 
these results are similar in other institutions or among our 
entire population. A larger analysis comparing our elderly 
population to other centers and comparing our elderly 
population to our nonelderly population would help to assess 
this. There is debate over the definition of elderly by a person’s 
chronological age, with a starting age ranging from 60-75.31 By 
choosing patients over 70 years, we better captured the aging 
population with comorbidities, however we decreased the 
sample size. Additionally, this analysis utilized descriptive 
statistics with some use of statistical tests. A post-hoc multi-
variate analysis was conducted, however applicability is limited 
due to the small number of patients and treatment failures in 
this analysis. A more robust, multi-variate analysis with more 
patients will be necessary to determine true impact of variables 
on treatment. While the DAAs used in this evaluation were 
highly effective, several new regimens have been approved 
since 2016, limiting the use of some regimens that were 
included in this analysis. The use of PrOD, SOF/SIM, SOF/RBV 
are no longer first line treatments due to the lower efficacy 
rates in some populations such as cirrhotics, and negative 
characteristics such as higher pill burden and drug interactions. 
While SIM/SOF had the lowest rate of SVR12 achievement, the 
use of other regimens did not correspond to lower SVR12 rates. 
The majority of patients received DAA regimens that are 
recommended by current guidelines, indicating that these 
findings could be replicated with current treatments. Though 
not statistically significant, the use of a multiple tablet DAAs 
negatively impacted SVR12 results in our population. Inclusion 
of newer regimens in our population would have helped 
determine if this is similar with recently approved regimens 
containing more than one tablet daily. 
  
Our institution is located in an urban setting, and thus this 
analysis includes more Hispanic patients and African American 
patients than typical clinical trials. More females were treated 
in our elderly cohort than typical clinical trials. Patients 
primarily presented with genotype 1a and 1b, which are the 
most common genotypes found in the US, increasing the 
generalizability of our results. Based on these findings, 
clinicians should be cognizant of the considerations needed for 
an elderly population. Clinical pharmacists should assess for 
drug-drug interactions and encourage medication adherence 
and treatment of patients as soon as HCV is discovered. 
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Conclusion 
The SVR12 in patients over the age of 70 at our institution was 
lower than that of the general population. Most treatment 
failures occurred in elderly patients with cirrhosis or other 
comorbidities such as diabetes, cardiovascular disease, or 
cognitive impairment, likely a result of patients living with HCV 
for longer. Higher overall pill burden did not impact attainment 
of SVR12, however DAAs with more than one tablet daily 
decreased SVR12 rates, which could be a result of cirrhotic 
and/or treatment experienced patients. Patients with higher 
pill burden or comorbidities are also at an increased risk of DDIs 
and AEs so additional precautions and monitoring should be 
taken. Further data is needed to confirm the impact of these 
and other factors on SVR12 attainment in an elderly patient 
population. 
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Table 1: Characteristics of Elderly Population >70 Years of Age 
Variable Value (Total n=62) 
Age (range), years 73 ± 2.88 (70-86) 
Female Gender 61% (n=38) 
Race  
African American 74% (n=46) 
Caucasian 15% (n=9) 
Hispanic 11% (n=7) 
Comorbidities 
Cirrhosis 58% (n=36) 
Diabetes 31% (n=19) 
Cardiovascular Disease 21% (n=13) 
Cognitive Impairment 10% (n=6) 
eGFR <60 ml/min 31% (n=19) 
Treatment Naive 65% (n=40) 
Genotype  
1a 51% (n=32) 
1b 40% (n=25) 
2 5% (n=3) 
1a/1b 2% (n=1) 
1a/3 2% (n=1) 
DAA Regimen 
Ledipasvir/Sofosbuvir (LDV/SOF) 
8 weeks 17% (n=11) 
12 weeks 45% (n=28) 
24 weeks 14% (n=9) 
Ledipasvir/Sofosbuvir + Ribavirin  (LDV/SOF + RIB) 
12 weeks n=1 
24 weeks n=1 
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Simeprevir + Sofosbuvir (SIM/SOF) 
12 weeks 4% (n=3) 
24 weeks 3% (n=2) 
Sofosbuvir + Ribavirin (SOF/RIB) 
12 weeks n=1 
16 weeks 3% (n=2) 
Elbasvir/Grazoprevir (EBR/GZR) 
12 weeks 3% (n=2) 
Othera 3% (n=2) 
a Other regimens include PrOD + RBV and SOF/daclatasvir + RBV 
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Table 2: Summary of Contributing Factors on SVR12 Attainmenta 
 
Contributing Factor Attained SVR12 
With Contributing 
Factor 
Attained SVR12 
Without 
Contributing Factor 
P value 
Comorbidity      
Cirrhosis 67% 100% 0.001 
Diabetes 68% 83.7% 0.303 
Cardiovascular Disease 77% 81.25% 0.728 
Cognitive Impairment 50% 83.63% 0.049 
eGFR <60 ml/min 84% 80.95% 0.608 
 SVR12 Attainment by Contributing Factor  
HCV Regimen Single Tablet 
Regimen  
Multi Tablet 
Regimen 
  
83.6% 66.7% 0.184 
Treatment History Treatment Naive  Treatment 
Experienced 
  
87% 68% 0.073 
Pill Burden  ≥9 tablets/day <9 tablets/day   
82% 79% 0.655 
Time to HCV Treatment <90 days  ≥90 days   
86.84% 69.56% 0.100 
a Factors evaluated using univariate analysis  
 
 
 
